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Summary The chemistry of the mitomycin C-related drug indoloquinone E09 would suggest that its mechanism of action is likely to involve
DNA damage after reductive activation. The ability of this agent to induce DNA damage in intact cells has been examined using alkaline filter
elution. After treatment with pharmacologically relevant concentrations of E09, both DNA strand breaks and interstrand cross-links were
detected in rat Walker tumour cells and human HT29 colon carcinoma cells. These cell lines express relatively high levels of DT-diaphorase
(NAD(P)H: quinone acceptor oxidoreductase), which is believed to be involved in E09 activation. The extent of DNA damage was increased
by approximately 30-fold under hypoxia in BE colon carcinoma cells that express non-functional DT-diaphorase, but this dramatic hypoxia
enhancement was not seen in HT-29 cells. These data are consistent with cytotoxicity studies that indicate that DT-diaphorase appears to be
important in E09 activation under aerobic conditions, but other enzymes may be more relevant under hypoxia. The involvement of DT-
diaphorase in DNA damage induction was further investigated using cell-free assays. DNA cross-links were detectable in plasmid DNA co-
incubated with E09, cofactor and DT-diaphorase but not in the absence of this enzyme. In contrast, using a Taq polymerase stop assay,
monofunctional alkylation was detected in plasmid DNA without metabolic activation, although the sequence selectivity was altered after
reduction catalysed by DT-diaphorase.
Keywords: DNA damage; E09; DT-diaphorase; sequence selectivity; bioreductive agent
The indoloquinone anti-cancer agent E09 (3-hydroxy-5-
aziridinyl-l-methyl-2-(H-indole-4,7-dione)prop-,B-en-a-ol; Figure
1) developed under the auspices of the EORTC (European
Organization for Research and Treatment ofCancer) (Oostveen &
Speckamp, 1987; Hendriks et al, 1993), is currently undergoing
clinical trial (Hendriks et al, 1993). Although results were
promising in phase I studies (Schellens et al, 1994), data from
phase II studies are not so favourable (Wanders et al, 1995;
Pavlidis et al, 1996). Its structural similarity to the prototype biore-
ductive alkylating agent mitomycin C would suggest that its cyto-
toxic mechanism is likely to involve DNA damage. After
one-electron reduction, E09 would be expected to generate the
semiquinone with concomitant formation ofoxygen radicals under
aerobic conditions. Both these species are potentially damaging to
DNA by inducing strand breaks. In theory, two-electron reduction
catalysed by DT-diaphorase (DT-D) should bypass this toxic
oxygen radical-producing stage. However, we have previously
shown thatE09, which is a good substrate for DT-D (Walton et al,
1991), is reduced to a highly oxygen-sensitive metabolite that
subsequently undergoes auto-oxidation under aerobic conditions
to generate a drug-based and oxygen-based radical (Bailey et al,
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1993). In addition, one- or two-electron reduction could facilitate
opening of the aziridine ring or activation of one or more of the
two hydroxyl side groups to produce a monofunctional or bifunc-
tional alkylating species capable of forming adducts with DNA.
The spectrum of metabolites formed is therefore likely to depend
on the levels and affinities ofvarious reducing enzymes within the
cell and the degree ofhypoxia (Workman, 1994).
The identity ofthe cytotoxic species and the precise mechanism
ofactivation ofE09 remain to be determined. However, consider-
able evidence supported the involvement of the two-electron-
reducing flavoenzyme DT-D in this activation process. Studies
involving panels of cell lines have shown a correlation between
DT-D activity and sensitivity to E09 under aerobic conditions
(Paull et al, 1994; Plumb et al, 1994 a and b; Robertson et al, 1994;
Smitskamp-Wilms et al, 1994; Collard et al, 1995; Fitzsimmons et
al, 1996), although a negative correlation has been reported under
hypoxia (Plumb et al, 1994b; Robertson et al, 1994). In addition,
DT-D both in the purified form (Bailey et al, 1992; Chen et al,
1995; Maliepaard et al, 1995) and in extracts ofDT-D-rich tumour
cells (Bailey etal, 1992; Walton et al, 1991, 1992a) has been shown
to catalyse reduction of E09. Further evidence has been provided
by experiments in which transfection ofthe human DT-diaphorase
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supplemented with 10% fetal calf serum, 1 mM glutamine and
antibiotics, penicillin and streptomycin (100 U ml-l and
100gg ml respectively). Rat Walker UK 256 tumour cells [both
Walker-sensitive cells and a subline with derived resistance to
chlorambucil (Walker resistant)] were grown as suspension
cultures in Dulbecco's minimal essential medium supplemented
with 10% horse serum, 1 mm glutamine and antibiotics (as
described above). Cells were maintained in a humidified incubator
at 37°C with 8% carbon dioxide. Figure 1 Chemical Structure of E09
gene into non-DT-diaphorase expressing rodent cells resulted in
increased sensitivity to E09 (Gustafson et al, 1996). Using recom-
binant DT-D, E09 hasbeen shown to act as abettersubstrate forrat
DT-D than forthe human ormurine enzyme (Chen etal, 1995). Not
surprisingly, however, E09 also acts as a substrate forother reduc-
tases, such as NADPH:cytochrome P450 reductase (Bailey et al,
1994a) and xanthine oxidase (Maliepaard et al, 1995).
Recently, some evidence has been provided for DNA damage as
a mechanism of E09-induced cytotoxicity. Electron spin reso-
nance (ESR) studies showed that reduction of E09 catalysed by
DT-D and NADPH:cytochrome P450 reductase generated a
drug-based radical, most probably the semiquinone, in addition to
oxygen radicals (Bailey et al, 1993, 1994a). These potentially
DNA-damaging species are probably responsible for the strand
breaks detected in plasmid DNA after DT-D-catalysed reduction
ofE09 (Walton et al, 1991, 1992a). Using a cell-free fluorescence
assay, DNA interstrand cross-links have also been detected in calf
thymus DNA after activation ofE09 by DT-D orxanthine oxidase
(Maliepaard et al, 1995). The extent of this damage was reduced
with decreasing pH from 7 to 5.5. No cross-links were observed in
the absence ofactivation.
In the present study, we have further examined DNA damage as
a potential mechanism of E09-induced cytotoxicity. Initially, the
potential ofE09 to cause DNA damage in intact cells at pharma-
cologically relevant concentrations was examined using clono-
genic assay and DNA alkaline filter elution. The role of DT-D in
the induction of DNA damage was investigated in cell-free
systems. A plasmid agarose gel method (Hartley et al, 1991) was
used for determination of DNA interstrand cross-links, and a
highly sensitive Taq polymerase stop assay (Ponti et al, 1991) was
used to examine the sequence selectivity ofDNA binding.
MATERIALS AND METHODS
Materials
E09 was kindly provided by Dr H Hendriks (EORTC New Drug
Development Office, Amsterdam, Netherlands). MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), dicoumarol
andNADH wereobtainedfrom SigmaChemical, Poole, Dorset, UK.
DT-D was purified as described previously (Knox et al, 1988). The
HT29 cells were obtained from the ATCC (Rockville, MD, USA)
and BEcells werekindly donatedby DrNW Gibson (Pfizer, Groton,
CT, USA).
Cell culture
The human colon carcinoma cell lines HT29 and BE were grown
as monolayer cultures in Eagle's minimal essential medium
Clonogenic assay
The sensitivity of both rat Walker-sensitive and -resistant cells
towards E09 was determined by clonogenic assay as described
previously (Knox et al, 1991). Drug was dissolved in dimethyl
sulphoxide (DMSO; < 1% final concentration) and treatment
was for 2 h at 37°C. The effect of dicoumarol (100-600gM) on
E09 (0.015 jiM)-induced cytotoxicity was also investigated in
Walker-sensitive cells as described by Roberts and co-workers
(Roberts et al, 1989).
DNA alkaline filter elution
DNA strand breaks andinterstrandcross-links were analysed in rat
Walker-sensitive, human HT29 and BE cells by DNA alkaline
filter elution. This method permits cross-links to be determined in
the presence ofstrand breaks. The latterincrease the rate ofelution
ofDNA through a filter while cross-links are assumed to retard it.
The method was essentially as described previously (Roberts and
Friedlos, 1987). Briefly, exponentially growing cells were radio-
labelled and drug treated as described below before irradiation
and elution.
Walker-sensitive cells (3 x 105 cells ml-') were radiolabelled for
24 h with either 3H-labelled thymidine (Amersham International,
Amersham, Bucks, UK) or '4C-labelled thymidine (Amersham
International) at a specific activity of 1 ,uCi ml-. These were then
harvested by centrifugation, washed twice in phosphate-buffered
saline (PBS) (calcium andmagnesiumfree) andresuspended togive
a cell density of 2 x 105 cells ml-' for drug treatment. Four repeat
doses of either 4 nm or 20nm (dissolved in a maximum final
concentration of 0.02% DMSO) E09 were applied to "IC-labelled
cells at 4-hourly intervals. After a further 12-h incubation period,
drug was removed by centrifugation, cells were washed twice in
medium and were prepared for elution. Control incubations
involved exposing cells to the solvent DMSO. CB 1954 (5-
(aziridin-l-yl)-2,4-dinitrobenzamide) induces a high frequency of
DNA interstrandcross-links inWalkercell DNA (Knox etal, 1988).
This agent(10 ,UM for 1.5 h) was thereforeusedas apositivecontrol.
HT29 and BE cells in exponential growth were harvested and
seeded at a density of 106 cells in 75-cm2 tissue culture flasks and
after a 6 to 8 h recovery period were radiolabelled for 72 h as
described for Walker cells. After removal of the radiolabel, cells
were resuspended in medium, seeded onto sterile, glass Petri
dishes (5 cm diameter) at a density of 1 x 106 cells per dish and
incubated at 37°C for 24 h before treatment. Cells ('4C-labelled)
were exposed to E09 (0.25 gM or 10gM) or vehicle (DMSO in
PBS) for 2 h at 37°C in a humidified atmosphere under aerobic
(5% carbon dioxide in air) or hypoxic (5% carbon dioxide in
nitrogen; British Oxygen Company, London, UK) conditions.
These concentrations were around the IC50 values ofE09 in HT29
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Figure 2 The effect of E09 on colony-forming ability of Walker-resistant (O)
and Walker-sensitive cells (-) after a 2-h exposure. Data are taken from an
individual experiment and were confirmed in at least one repeat assay. Each
of the data points are an average of four repeat assays carried out within a
single experiment
and BE cells, respectively, for a 3-h exposure under aerobic condi-
tions (Plumb and Workman, 1994).
After treatment, the Walker-sensitive, HT29 and BE cells (I x
106 cells ml-') were harvested, resuspended in PBS and divided to
provide two groups of cells, one for irradiation and the other to
remain unirradiated; this was to allow the examination of both
interstrand cross-links and strand breaks. The '4C-labelled treated
samples for irradiation were given a dose of6 Gy. The 3H-labelled
control, untreated cells were irradiated with 1.5 Gy for all experi-
ments. Equal volumes of 14C-labelled, treated cells and 3H-
labelled, untreated control cells were mixed to give a final cell
concentration of 2 x 104 cells ml-'. These were then eluted, and
DNA strand-break and cross-link frequencies were determined as
reported previously (Roberts and Friedlos, 1987).
Plasmid cross-linking assay
The method used to determine plasmid DNA interstrand cross-link
formation in a cell-free system was based on that described by
Hartley et al (1991). BamH1-linearized, dephosphorylated pBR322
DNA (Northumbria Biologicals, Cramlington, Northumbria, UK)
was 5'-end-labelled with [y-32P]ATP (5000 Ci mmol-', Amersham
International) using T4 polynucleotide kinase. After ethanol
precipitation, the DNA was resuspended to give 100 ng pl-'.
End-labelled DNA (10 ng perreaction) was incubated withE09
(0.01 gIM-100 ,M final concentration), purified rat Walker cell
DT-D (0.00175-0.175 ,ug) and 1 mm NADH in triethanolamine
buffer (TEA; 25 mm, 1 mm EDTA, pH 7.2) for 2 h at 37°C.
Control experiments involved omission ofeither drug, cofactor or
enzyme as well as a sample of untreated DNA. Reactions were
terminated by addition of an equal volume of stop solution (0.6 M
sodium acetate, 20 mm EDTA, 100 ,ug ml-' tRNA). Samples were
then precipitated, denatured and electrophoresed as described
previously (Hartley et al, 1991).
Taq DNA polymerase assay
The sequence selectivity of E09 alkylation of DNA in a cell-free
system was determined using the Taq polymerase stop assay (Ponti
et al, 1991).
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Figure 3 Alkaline elution profiles for rat Walker tumour cells exposed to
four repeat doses of 4 or 20 nm E09 given at 4-hourly intervals under aerobic
conditions. (A) shows data obtained using unirradiated cells and (B) results
seen with irradiated cells. CB 1954 was also included as a positive control
because of its known ability to induce DNA interstrand cross-links in this
system. Data are taken from an individual experiment and were typical of the
trend seen in other similar experiments
BamHI-digested pBR322 DNA was incubated for 2 h at 370C in
the presence of E09 (0.1-100 JM in DMSO at 1% final DMSO
concentration), 1 mm NADH and purified rat Walker DT-D
(0.175 ,ug) in 25 mM triethanolamine, 1 mmEDTA, pH 7.2, to give a
final volume of50 ul. Control reactions involved omission ofone or
more of the reaction constituents. In addition, a positive control,
chlorambucil (100 ,UM in DMSO 1% final concentration), was
included. After drug treatment the reaction was terminated by addi-
tion ofan equal volume (50gl) ofstop buffer (0.6 M sodium acetate,
20 mm EDTA, 100jg ml' tRNA) and DNA was precipitated with
three volumes ofethanol and then washed with 70% ethanol.
A synthetic oligonucleotide primer with the sequence 5'-TATGC-
GACTCCTGCATTAGG-3' was 5'- end labelled before amplifica-
tion, with [,y-32P]ATP (10 lCi) using T4 kinase. Amplification,
electrophoresis and autoradiography were then carried out as previ-
ously reported (Ponti et al, 1991).
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RESULTS
Cell survival assays
Clonogenic assays using Walker-sensitive and resistant lines
showed E09 to be an extremely potent cytotoxin (Figure 2). A
clear differential in toxicity was demonstrated between the resis-
tant and sensitive strains ofWalker cells in response to E09. When
dicoumarol was included in the Walker-sensitive cell survival
assays for E09, some protection against cytotoxicity was noted
(data not shown).
DNA damage in intact cells
Walker-sensitive cells exposed under aerobic conditions to four
repeat doses ofeither 4 nm or 20 nM E09 showed evidence ofboth
DNA interstrand cross-link and DNA strand break induction
(Figure 3). At 12 h after addition of 20 mM E09, the strand break
frequency was 3.26 strand breaks per 109 daltons of DNA and
cross-link frequency (corrected for DNA strand breaks) was 1.14
cross-links per 109 daltons of DNA, while at 4 nM E09 the
frequency of strand breaks was 0.75 strand breaks per 109 daltons
of DNA and cross-link frequency was 0.66 cross-links per 109
daltons of DNA.
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Figure 5 The effect of altering enzyme and drug concentration on E09-
induced DNA interstrand cross-link frequency after activation by DT-D in the
presence of cofactor and NADH. Standard reaction conditions included
pBR322 (10 ng), E09 (1 gM), NADH (100gM) and DT-D (175 ng). DNA
damage from the agarose gel was quantified by densitometry. Lanes: A,
plasmid DNA untreated and undenatured as double-stranded control; B,
plasmid denatured, untreated control; C, no NADH control; D, no drug
control; E-l, increasing E09 concentration (0.01. 0.1, 1, 10 and 100gM);
J, no enzyme control; K-O, increasing DT-D concentration (0.175, 1.75, 17.5,
175 ng); P, 1 gM E09 in the absence of enzyme and cofactor; Q, 10 gM E09
in the absence of enzyme and cofactor
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Figure 4 Alkaline elution profiles for (A and B) HT29 and (C and D) BE cells exposed to 0.25gM E09 for a period of 2 h under (A and C) aerobic and (B and
D) hypoxic conditions. V, E09-treated irradiated cells; A, control unrradiated cells; *, control irradiated cells; *, E09 treated unirradiated cells. Data were
taken from an individual experiment, although similar trends were seen in repeat experiments carried out under identical conditions
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Aerobic exposure ofHT29 cells to 0.25 gM E09 also resulted in
DNA damage as detected by alkaline filter elution (Figure 4). The
average DNA strand break frequency was 4.62 DNA strand breaks
per 109 daltons DNA. The irradiated E09-treated sample did not
appear to show impaired elution kinetics as a result ofthe presence
of strand breaks that obscured their visualization. However, on
application of the formula (Roberts and Friedlos, 1987) to correct
for the strand breaks, 0.59 cross-links per 109 daltons DNA were
evident. In contrast to HT29 cells, this concentration of E09 was
non-toxic to BE cells (Plumb and Workman, 1994) and induced
little DNA damage in this cell line. The frequency of DNA
damage was 0.147 cross-links per 109 daltons of DNA and 0.247
strand breaks per 109 daltons of DNA.
When the concentration of E09 was increased to 1OiM, little
further increase in DNA damage above that induced by 0.25 gM
under aerobic conditions was observed in HT29 cells (data not
shown). In contrast, for BE cells, a significant increase in the quan-
tity of DNA strand breaks induced was observed with a frequency
of6.42 strand breaks per 109 daltons ofDNA, although DNA cross-
link induction was still low at 0.37 lesions per 109 daltons ofDNA.
Experiments were carried out to compare the DNA damage
under aerobic and hypoxic conditions. In HT29 cells (Figure 4), a
similar degree ofDNA strand breaks and cross-links were induced
under hypoxic conditions as in the presence ofair (2.48 lesions per
109 daltons DNA and 0.67 lesions per 109 daltons DNA respec-
tively). In BE cells, hypoxia dramatically increased the DNA
damage induced by E09 in terms of both the DNA interstrand
cross-links and DNA strand breaks. The difference between
aerobic and hypoxic DNA damage was greater at the lower
concentration of 0.25 gm E09 (Figure 4). The strand break
frequency was 1.98 lesions per 109 daltons DNA, and DNA inter-
strand cross-link frequency was 3.36 lesions per 109 daltons DNA.
The frequency of strand breaks and cross-links increased approxi-
mately eight- and 30-fold, respectively, under hypoxic compared
with oxic conditions.
DNA cross-links with purified DT-D
The DNA cross-linking ability of E09 in a cell-free system in the
presence or absence ofDT-D and cofactor NADH was determined
using an agarose gel method (Hartley et al, 1991). The presence of
a cross-link between the two DNA strands prevents complete
separation of the strands upon denaturation such that the cross-
linked DNA reanneals in a neutral gel to run as double stranded.
Quantification of the double-stranded DNA therefore gives a
measure of the extent of cross-linking in a given DNA sample
(Hartley et al, 1991). Cross-link formation in plasmid pBR322
DNA was detected after incubation ofE09 with DT-D in the pres-
ence of NADH (Figure 5). The extent of this damage increased
with increasing enzyme and drug concentration up to 1 gM E09,
beyond which a decrease in the degree of cross-linking occurred.
DNA cross-links were not evident in controls in which either drug
or cofactor was omitted. A very small percentage of cross-links
were however observed in the control in which drug and cofactor
were incubated without enzyme (not shown).
Sequence selectivity of E09 binding
The results obtained for the analysis ofthe sequence selectivity of
E09 alkylation in a cell-free system are presented in Figure 6. In
the non-drug-treated sample (Figure 6, lane A), the majority ofthe
560-
570-
A B C D E F G H I J
Figure 6 Autoradiogram of a polyacrylamide gel showing the sequence
selectivity of E09 adduct formation with DNA determined using the Taq
polymerase stop assay. Standard reaction conditions included E09 (100 gM),
NADH (1 mM), DT-D (0.175 ,ug) and pBR322 DNA (10 ng). Lanes: A,
untreated DNA control; B, chlorambucil-treated DNA; C-E, controls in which
(C) NADH or (D) enzyme were omitted or (E) when drug was incubated with
DNA alone. Finally, lanes F-J show the effect of increasing drug
concentration (0, 0.1, 1, 10 and 100 gM) on DNA adduct formation. The
arrows indicate a selection of bases in which the alkylation pattern has been
altered with every ten base numbers given for reference. Data were
confirmed in an independent repeat experiment
untreated DNA has undergone complete chain elongation. This
generated an intense band corresponding to a full-length fragment
of 263 base pairs visible at the top of the gel, with only a faint
background of bands corresponding to shorter length fragments
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(Figure 6, lane A). Chlorambucil (the positive control) exhibited a
clearpattern ofbands (Figure 6, laneB), indicating the presence of
covalent lesions on the DNA that block progression of the poly-
merase. The lesions seen for chlorambucil were in agreement with
those seen previously for the nitrogen mustards using the same
assay (Ponti et al, 1991). E09 alkylated DNA efficiently even in
the absence of activation (Figure 6, lane E). The lesions were
again predominantly at guanine residues but the banding pattern
for E09 was consistently different to that seen for chlorambucil
(Figure 6, lane B). The differences included sites alkylated
strongly by chlorambucil (Figure 6, lane B) that were alkylated
weakly by E09 (Figure 6, lane E), e.g. guanines at base positions
535-537, and sites alkylated strongly by E09 and weakly by
chlorambucil, e.g. base positions 497, 515 and 527. Addition of
cofactor did not alter the pattern appreciably (Figure 6, lane D).
When E09 was omitted (Figure 6, lane F) or was at low concen-
tration (Figure 6, lane G), no damage above the control (lane A)
was observed.
For incubations containing DT-D, either in the presence (Figure
6, lanes G-J) or in the absence of cofactor (Figure 6, lane C), a
reduction in band intensity was observed indicative of fewer
lesions. When E09 had been incubated with acomplete activating
system consisting of cofactor, NADH and DT-D (Figure 6, lanes
H-J), a different banding pattern was observed to that of drug
alone (Figure 6, lane E), with binding being more specific after
enzyme activation. Thus, some bases were modified with activated
E09 (Figure 6, lane J) that were not alkylated by either chloram-
bucil (Figure 6, lane B) or unactivated drug (Figure 6, lanes C-E).
These are most clearly evident in the top portion of the gel
indicatedby arrows.
DISCUSSION
The chemical structure of this investigational drug suggests that
the cytotoxic mechanism of E09 involves DNA damage, as has
been reported for other quinone bioreductive alkylating agents,
such as mitomycin C (Siegel et al, 1990a andb). The aziridine and
hydroxyl leaving groups may be activated to alkylating species
after reduction and could lead to DNA cross-links. In addition,
strand breaks may be caused by oxygen-based radicals generated
after one- or two-electron reduction (Bailey etal, 1993, 1994b).
The Walker tumour and the cell line derived from it (Walker
sensitive) are particularly sensitive to difunctional alkylating
agents (Rosenoer et al, 1966). A resistant subline, designated
Walker resistant, arose as a result of continual exposure to
chlorambucil in vitro (Knox et al, 1991). A range of difunctional
alkylating agents that are capable of inducing DNA interstrand
cross-links are particularly toxic towards the Walker-sensitive
cells but are much less active against Walker-resistant cells (Knox
et al, 1991). This differential toxicity therefore appears to be
indicative of a compound whose mechanism of cytotoxicity
involves difunctional alkylation. As E09 acted as a more potent
cytotoxin to Walker-sensitive cells than to Walker-resistant cells,
this suggested that DNA cross-linking was involved in the mode
of action of this agent. This was confirmed by alkaline elution
experiments in which both cross-links and strand breaks were
detectable.
Both Walker-sensitive and -resistant cells express large amounts
of DT-D (Knox et al, 1991), an enzyme shown previously to
metabolize E09 (Bailey et al, 1992; Walton et al, 1991, 1992a).
The sensitivity of the parental Walker-sensitive cells (Bailey et al,
1992; Walton et al, 1991, 1992a) suggested that this enzyme may
play a role in activation ofE09 to a DNA-damaging species. This
was supported by studies using a pair of human colon carcinoma
cell lines, HT29 and BE. HT29 cells, which contain ahigh level of
DT-D, were more sensitive to E09 under aerobic conditions than
BE cells, which do not express a functional form of the enzyme
(Plumb andWorkman, 1994; Walton etal, 1992b). A similarcorre-
lation between levels ofDT-D and sensitivity to E09 has also been
reported for a large range of cell lines by other investigators
(Collard et al, 1995; Plumb et al, 1994a and b; Robertson et al,
1994; Smitskamp-Wilms et al, 1994). Interestingly, underhypoxia,
the BE cells were greatly sensitized to E09, whereas little effect
was observed with the HT29 cells (Plumb and Workman, 1994).
Although others have shown that E09 causes DNA damage in
cell-free systems, data presented in this paper provide the first
demonstration of E09-induced DNA damage in intact cells.
Treatment of HT29 cells with a cytotoxic dose of E09 (0.25 gM)
induced both DNA strand breaks and interstrand cross-links.
However, this concentration did not result in substantial DNA
damage in BE cells. Thus, the trend in DNA damage correlates
well with the cytotoxic potency of E09. Increasing E09 concen-
tration to 10gM (- the IC50 value for BE cells) caused a large
amount of strand breaks in their DNA. Hence, a correlation
between DNA damage and cytotoxicity was again apparent. Only
a small amount of cross-links was induced in BE cells at this
concentration, and this may reflect a different mechanism ofcyto-
toxicity to that occurring with HT29 cells. Incubations carried out
under hypoxic conditions showed little change in strand break
induction in HT29 cell DNA, although a small increase in DNA
cross-link frequency was observed in some experiments. This
correlates with the modest 2.9-fold increase in cytotoxicity seen
under hypoxia in HT29 cells (Plumb and Workman, 1994).
Interestingly, BE cells showed a dramatic 30-fold increase in the
extent of cross-links formed when hypoxic conditions prevailed.
This may explain the 1000-3000 hypoxic cytotoxicity differential
reported by Plumb and Workman (1994). These data support the
involvement of DT-D in the aerobic activation of E09 to a cyto-
toxic species, whereas other enzymes, e.g. NADPH: cytochrome
P450 reductase, may be important for DNA damage and cytotoxi-
city under hypoxia. The lack of hypoxic sensitization of HT29
cells to E09 could reflect a higher affinity of the drug for DT-D
compared with one-electron-reducing enzymes.
As a complementary approach to alkaline elution, cell-free
assays have been used to investigate the role ofDT-D in activation
of E09 to the damaging species. Using this type of approach,
Walton and co-workers provided early evidence for the ability of
rat DT-D to catalyse conversion ofE09 to a plasmid DNA-strand
breaking species (Walton et al, 1991, 1992a). Furthermore, using a
fluorescence assay, others have also shown that rat DT-D and
xanthine dehydrogenase are able to activate E09 to cross-link calf
thymus DNA (Maliepaard et al, 1995). Here, we have used an
alternative agarose gel-plasmid method based on the conversion
of single-stranded DNA to double-stranded DNA in the presence
of cross-links. When E09 was incubated with rat DT-D and
cofactor, an increase in the percentage of double-stranded DNA
was observed compared with the control, indicating that DNA
cross-links had been induced. The level of cross-links increased
with both Increasing drug and DT-D concentration up to 1 ,UM, at
which almost complete conversion of single-stranded to double-
stranded DNA was observed. Interestingly, at drug concentrations
above 1IM, a decrease in DNA interstrand cross-linking occurred.
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It is possible that substrate inhibition occurs or that E09 is cross-
linking to enzyme and thus inactivating it, as has been described
for mitomycin C at physiological pH (Siegel et al, 1992). In
control incubations in which either drug, cofactor or enzyme were
omitted, only background levels of damage were observed,
showing that a complete activating system is required to convert
E09 to a bifunctional alkylating species. After reductive activa-
tion, E09 was found to cross-link plasmid DNA more efficiently
than an equivalent concentration of the bifunctional alkylating
agent chlorambucil. Thus, these experiments have confirmed that
purified DT-D catalysed reduction of E09 results in activation of
the compound to a difunctional alkylating species capable of
cross-linking plasmid DNA. In contrast, Phillips and co-workers
(Phillips et al, 1996) did not observe DNA cross-links after activa-
tion ofE09 by human DT-D using the same assay. The reason for
these differing results is unknown but is likely to be due to kinetic
differences between the human and the rodent enzyme.
The specificity ofdrug binding to particular sequences in DNA
may be relevant to anti-tumour activity. Understanding this selec-
tivity may permit rational design of compounds to target specific
sequences ofnucleotides. The Taq polymerase stop assay was used
to examine the sequence selectivity of covalent modification to
DNA by E09.
In contrast to the cross-linking results, DNA alkylation by E09
was observed in the absence of activation. It is likely that these
covalent adducts are due to monofunctional alkylation through the
aziridine moiety. Aziridines are highly reactive groups that can
readily bind to nucleophiles. Binding appears to occur predomi-
nantly at guanine residues, which is consistent with results
obtained for other aziridine-containing compounds (Mattes et al,
1986; Lee et al, 1992). This may be explained by the suggestion
that alkylation is related to the electrostatic potential of guanine
N-7 (Kohn et al, 1987). Electrostatic potential differs according to
the base adjacent to the guanine, with the most negative bases
being located in runs of guanines (Pullman and Pullman, 1981).
Interestingly, the DNA alkylation binding pattern seen withE09 is
distinct from thatofchlorambucil. Inparticular, the overall amount
of binding of E09 to guanine residues was reduced while some
bases, such as position 527 (Figure 6, Lane E), were alkylated
more strongly by E09 than chlorambucil. It has been reported
(Kohn et al, 1987) that the non-alkylating portion of the molecule
can influence the sequence selectivity ofalkylation.
When DT-D was present in the reaction, a decreased banding
intensity was observed, which may be as a result ofdrug binding to
the enzyme protein. Nevertheless, in the presence of a complete
enzyme-activating system, the pattern of DNA modification
induced by E09 was distinctly different to that obtained by direct
monofunctional alkylation. After enzyme activation, the compound
appeared even more selective, binding to fewer and different
sequences than when unactivated. A change in sequence selectivity
after activation by DT-D has been reported previously for the
aziridinyl benzoquinones Methyl DZQ and DZQ (Lee et al, 1992).
It is possible that one orboth ofthe two hydroxyl leaving groups
may be activated to alkylating moieties after enzymatic reduction.
These together could lead to cross-link induction. Alternatively,
either one of these could potentially be involved in cross-link
formation, with the activated aziridine group forming the second
arm ofthe cross-link. Activation to a bifunctional alkylating agent
may result in drug being able to cause cross-links at certain
sequences only and thus restricting lesions to fewer and more
specific sites. A further complication may exist in the fact that
these concentrations ofreaction constituents would be expected to
generate damaging oxygen radical species thathave been shown to
induce strand breaks in DNA under aerobic conditions (Bailey et
al, 1993; Walton et al, 1991, 1992a). Strand breaks could poten-
tially shorten the fragments of DNA and thus give artifactual
results mimicking those ofa covalent lesion.
In summary, there is good evidence that DNA damage is
involved in the mechanism ofcytotoxicity ofE09. We have shown
for the first time that DNA damage is induced in intact cells after
treatment with E09 at relevant cytotoxic concentrations of the
drug with both DNA strand breaks and interstrand cross-links
being observed. Purified DT-D can activate E09 to a species
capable of inducing DNA interstrand cross-links. In contrast to
DNA cross-linking, monofunctional alkylation by E09 occurs in
the absence of enzyme activation. However, the pattern of DNA
sequence selectivity is different to that seen after reduction
catalysedby DT-D. It is also clearthat DNA interstrand cross-links
can be formed under hypoxic conditions in cell lines lacking func-
tional DT-D, thereby explaining the interesting cell cytotoxicity
results (Plumb and Workman, 1994) and indicating the involve-
ment of other enzymes in activation of E09 to a DNA-damaging
species under hypoxic conditions. The role played by various
enzymes in activation of E09 in the intact cell is likely to vary
depending on their levels and affinities for E09 as well as the
levels of hypoxia (Workman, 1994). The precise identity of the
cytotoxic, DNA-damaging species remains undetermined.
The present results may be of use in the interpretation of the
clinical trial data with E09 and in the design of future clinical
studies, as well as in the development of new bioreductive agents
ofthis type.
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